Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature

  • Authors:
    • Xueli Zhang
    • Huiqiao Li
    • Min Zhu
    • Yuhui Zhang
  • View Affiliations

  • Published online on: March 11, 2015     https://doi.org/10.3892/ol.2015.3026
  • Pages: 2419-2421
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Interstitial lung disease (ILD) is a severe adverse effect of gefitinib treatment. Re‑administration of gefitinib to patients suspected of suffering from gefitinib‑induced ILD requires cautious consideration. In the majority of cases, gefitinib is not re‑administered to such patients. The present study reports a case of advanced lung adenocarcinoma, where the patient developed gefitinib‑induced ILD and gefitinib was re‑administered at 3.5 months after discontinuation of gefitinib treatment. Initially, the patient achieved partial clinical remission, but developed diffuse ILD following gefitinib administration for 5 months. Following the onset of ILD, gefitinib was discontinued immediately and low‑dose corticosteroids were administered at the early stages of ILD. Subsequent to recovery from the lung injury, gefitinib was re‑administered along with N‑acetylcysteine. The patient presented with good lung adenocarcinoma control and did not experience a recurrence of ILD for >16 months. Thus, early discontinuation and gefitinib re‑administration with N‑acetylcysteine may be a potential novel treatment strategy for gefitinib‑induced ILD.
View Figures
View References

Related Articles

Journal Cover

May-2015
Volume 9 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang X, Li H, Zhu M and Zhang Y: Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature. Oncol Lett 9: 2419-2421, 2015
APA
Zhang, X., Li, H., Zhu, M., & Zhang, Y. (2015). Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature. Oncology Letters, 9, 2419-2421. https://doi.org/10.3892/ol.2015.3026
MLA
Zhang, X., Li, H., Zhu, M., Zhang, Y."Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature". Oncology Letters 9.5 (2015): 2419-2421.
Chicago
Zhang, X., Li, H., Zhu, M., Zhang, Y."Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature". Oncology Letters 9, no. 5 (2015): 2419-2421. https://doi.org/10.3892/ol.2015.3026